Erratum to: FGFR2 mutation confers a less drastic gain of function in mesenchymal stem cells than in fibroblasts(Stem Cell Rev and Rep, DOI:10.1007/s12015-011-9327-6);FGFR2 Mutation Confers a Less Drastic Gain of Function in Mesenchymal Stem Cells Than in Fibroblasts

Stem Cell Reviews and Reports

Volumn 8, Issue 3, 2012, Pages 685-695

  Yeh, Erika ^a   Atique, Rodrigo ^a   Ishiy, Felipe A A ^a   Fanganiello, Roberto Dalto ^a   Alonso, Nivaldo ^a   Matushita, Hamilton ^a   da Rocha, Katia Maria ^a   Passos Bueno, Maria Rita ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Apert syndrome; FGFR2; Fibroblasts; Mesenchymal stem cells; Osteogenesis

Indexed keywords

EID: 84865554217     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-013-9470-3     Document Type: Erratum

References (54)

1. Cohen, M. M. J. M. (2000). R. E. Craniosynostosis: Diagnosis, evaluation and manegement (2nd ed.). USA: Oxford University Press.
2. Cohen, M. M., Jr., & Kreiborg, S. (1993). Skeletal abnormalities in the Apert syndrome. American Journal of Medical Genetics, 47(5), 624-632.
3. Murnaghan, L. M., Thurgur, C. H., Forster, B. B., Sawatzky, B. J., Hawkins, R., & Tredwell, S. J. (2007). A clinicoradiologic study of the shoulder in Apert syndrome. Journal of Pediatric Orthopedics, 27(7), 838-843.
4. McHugh, T., Wyers, M., & King, E. (2007). MRI characterization of the glenohumeral joint in Apert syndrome. Pediatric Radiology, 37(6), 596-599.
5. Ornitz, D. M. (2000). FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays, 22(2), 108-112.
6. Ibrahimi, O. A., Eliseenkova, A. V., Plotnikov, A. N., Yu, K., Ornitz, D. M., & Mohammadi, M. (2001). Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Proceedings of the National Academy of Sciences of the United States of America, 98(13), 7182-7187.
7. Beenken, A. O. (2011) L. A.
8. Yang, F., Wang, Y., Zhang, Z., Hsu, B., Jabs, E. W., & Elisseeff, J. H. (2008). The study of abnormal bone development in the Apert syndrome Fgfr2+/S252W mouse using a 3D hydrogel culture model. Bone, 43(1), 55-63.
9. Lomri, A., Lemonnier, J., Hott, M., et al. (1998). Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome. The Journal of Clinical Investigation, 101(6), 1310-1317.
10. Mansukhani, A., Bellosta, P., Sahni, M., & Basilico, C. (2000). Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. The Journal of Cell Biology, 149(6), 1297-1308.
11. Mestas, J., & Hughes, C. C. (2004). Of mice and not men: differences between mouse and human immunology. Journal of Immunology, 172(5), 2731-2738.
12. Haley, P. J. (2003). Species differences in the structure and function of the immune system. Toxicology, 188(1), 49-71.
13. Bulfield, G., Siller, W. G., Wight, P. A., & Moore, K. J. (1984). X chromosome-linked muscular dystrophy (mdx) in the mouse. Proceedings of the National Academy of Sciences of the United States of America, 81(4), 1189-1192.
14. Dhillon, K. K., Sidorova, J. M., Albertson, T. M., et al. (2009). Divergent cellular phenotypes of human and mouse cells lacking the Werner syndrome RecQ helicase. DNA Repair, 9(1), 11-22.
15. Harries, L. W., Brown, J. E., & Gloyn, A. L. (2009). Species-specific differences in the expression of the HNF1A, HNF1B and HNF4A genes. PloS one, 4(11), e7855.
16. Twigg, S. R., Healy, C., Babbs, C., et al. (2009). Skeletal analysis of the Fgfr3(P244R) mouse, a genetic model for the Muenke craniosynostosis syndrome. Developmental Dynamics, 238(2), 331-342.
17. Fanganiello, R. D., Sertie, A. L., Reis, E. M., et al. (2007). Apert p. Ser252Trp mutation in FGFR2 alters osteogenic potential and gene expression of cranial periosteal cells. Molecular Medicine (Cambridge, Mass), 13(7-8), 422-442.
18. Slater, B. J., Lenton, K. A., Kwan, M. D., Gupta, D. M., Wan, D. C., & Longaker, M. T. (2008). Cranial sutures: a brief review. Plastic and Reconstructive Surgery, 121(4), 170e-178e.
19. Foster, K. A., Frim, D. M., & McKinnon, M. (2008). Recurrence of synostosis following surgical repair of craniosynostosis. Plastic and Reconstructive Surgery, 121(3), 70e-76e.
20. Hopper, R. A., Zhang, J. R., Fourasier, V. L., et al. (2001). Effect of isolation of periosteum and dura on the healing of rabbit calvarial inlay bone grafts. Plastic and Reconstructive Surgery, 107(2), 454-462.
21. Ozerdem, O. R., Anlatici, R., Bahar, T., et al. (2003). Roles of periosteum, dura, and adjacent bone on healing of cranial osteonecrosis. The Journal of Craniofacial Surgery, 14(3), 371-379. discussion 80-2.
22. Ito, Y., Sanyal, A., Fitzsimmons, J. S., Mello, M. A., & O'Driscoll, S. W. (2001). Histomorphological and proliferative characterization of developing periosteal neochondrocytes in vitro. Journal of Orthopaedic Research, 19(3), 405-413.
23. Orwoll, E. (2006). Genetic aspects of osteoporosis. Annales d'endocrinologie, 67(2), 113.
24. Allen, M. R., Hock, J. M., & Burr, D. B. (2004). Periosteum: biology, regulation, and response to osteoporosis therapies. Bone, 35(5), 1003-1012.
25. Squier, C. A., Ghoneim, S., & Kremenak, C. R. (1990). Ultrastructure of the periosteum from membrane bone. Journal of Anatomy, 171, 233-239.
26. Colnot, C. (2009). Skeletal cell fate decisions within periosteum and bone marrow during bone regeneration. Journal of Bone and Mineral Research, 24(2), 274-282.
27. Bullaughey, K., Chavarria, C. I., Coop, G., & Gilad, Y. (2009). Expression quantitative trait loci detected in cell lines are often present in primary tissues. Human Molecular Genetics, 18(22), 4296-4303.
28. Gallea, S., Lallemand, F., Atfi, A., et al. (2001). Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12 cells. Bone, 28(5), 491-498.
29. Liu, H., Liu, Y., Viggeswarapu, M., Zheng, Z., Titus, L., & Boden, S. D. (2010). Activation of c-Jun NH(2)-terminal kinase 1 increases cellular responsiveness to BMP-2 and decreases binding of inhibitory Smad6 to the type I BMP receptor. Journal of Bone and Mineral Research.
30. Matsuguchi, T., Chiba, N., Bandow, K., Kakimoto, K., Masuda, A., & Ohnishi, T. (2009). JNK activity is essential for Atf4 expression and late-stage osteoblast differentiation. Journal of Bone and Mineral Research, 24(3), 398-410.
31. Guicheux, J., Lemonnier, J., Ghayor, C., Suzuki, A., Palmer, G., & Caverzasio, J. (2003). Activation of p38 mitogen-activated protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation. Journal of Bone and Mineral Research, 18(11), 2060-2068.
32. Li, C., Scott, D. A., Hatch, E., Tian, X., & Mansour, S. L. (2007). Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development. Development (Cambridge, England), 134(1), 167-176.
33. ImageJ. U. S. National Institutes of Health, 1997-2009. (Accessed 5 October 2009, at http://rsb. info. nih. gov/ij/).
34. Gregory, C. A., Gunn, W. G., Peister, A., & Prockop, D. J. (2004). An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Analytical Biochemistry, 329(1), 77-84.
35. de Mendonca Costa, A., Bueno, D. F., Martins, M. T., et al. (2008). Reconstruction of large cranial defects in nonimmunosuppressed experimental design with human dental pulp stem cells. The Journal of Craniofacial Surgery, 19(1), 204-210.
36. Bennett, B. L., Sasaki, D. T., Murray, B. W., et al. (2001). SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proceedings of the National Academy of Sciences of the United States of America, 98(24), 13681-13686.
37. Joiakim, A., Mathieu, P. A., Palermo, C., Gasiewicz, T. A., & Reiners, J. J., Jr. (2003). The Jun N-terminal kinase inhibitor SP600125 is a ligand and antagonist of the aryl hydrocarbon receptor. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 31(11), 1279-1282.
38. Posnick, J. C., Armstrong, D., & Bite, U. (1995). Crouzon and Apert syndromes: intracranial volume measurements before and after cranio-orbital reshaping in childhood. Plastic and Reconstructive Surgery, 96(3), 539-548.
39. Bueno, D. F., Kerkis, I., Costa, A. M., et al. (2009). New source of muscle-derived stem cells with potential for alveolar bone reconstruction in cleft lip and/or palate patients. Tissue Engineering Part A, 15(2), 427-435.
40. Miraoui, H., Oudina, K., Petite, H., Tanimoto, Y., Moriyama, K., & Marie, P. J. (2009). Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/2 and protein kinase C signaling. The Journal of Biological Chemistry, 284(8), 4897-4904.
41. Holmes, G., Rothschild, G., Roy, U. B., Deng, C. X., Mansukhani, A., & Basilico, C. (2009). Early onset of craniosynostosis in an Apert mouse model reveals critical features of this pathology. Developmental Biology, 328(2), 273-284.
42. Wang, Y., Xiao, R., Yang, F., et al. (2005). Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse. Development (Cambridge, England), 132(15), 3537-3548.
43. Su, N., Sun, Q., Li, C., et al. (2010). Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis. Human Molecular Genetics, 19(7), 1199-1210.
44. Freshney, R. I. (2005). Culture of animal cells: A manual of basic technique (5th ed). Wiley-Liss.
45. Ibrahimi, O. A., Zhang, F., Eliseenkova, A. V., Itoh, N., Linhardt, R. J., & Mohammadi, M. (2004). Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Human Molecular Genetics, 13(19), 2313-2324.
46. Lemonnier, J., Hay, E., Delannoy, P., et al. (2001). Increased osteoblast apoptosis in apert craniosynostosis: role of protein kinase C and interleukin-1. The American Journal of Pathology, 158(5), 1833-1842.
47. Scadden, D. T. (2006). The stem-cell niche as an entity of action. Nature, 441(7097), 1075-1079.
48. Shukla, V., Coumoul, X., Wang, R. H., Kim, H. S., & Deng, C. X. (2007). RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nature Genetics, 39(9), 1145-1150.
49. Lopez-Bergami, P., Huang, C., Goydos, J. S., et al. (2007). Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell, 11(5), 447-460.
50. Beenken, A., & Mohammadi, M. (2009). The FGF family: biology, pathophysiology and therapy. Nature Reviews, 8(3), 235-253.
51. Ge, C., Xiao, G., Jiang, D., & Franceschi, R. T. (2007). Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. The Journal of Cell Biology, 176(5), 709-718.
52. Marie, P. J. (2003). Fibroblast growth factor signaling controlling osteoblast differentiation. Gene, 316, 23-32.
53. Wang, Y., Sun, M., Uhlhorn, V. L., et al. Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice. BMC Developmental Biology, 10, 22.
54. Yin, L., Du, X., Li, C., et al. (2008). A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis. Bone, 42(4), 631-643.